Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans

Shiota, Seiji; Reddy, Ram; Alsarraj, Abeer; El–Serag, Hashem B.; Graham, David Y.

doi:10.1016/j.cgh.2015.02.005

Cited by 136 publications

(132 citation statements)

References 41 publications

Supporting

Mentioning

127

Contrasting

Unclassified

Order By: Relevance

“…Th ere is little data to guide clinicians on either fl uoroquinolone resistance rates in North America or the impact of resistance on the effi cacy of fl uoroquinolone-containing treatment regimens. Th e little data that exist, suggest that fl uoroquinolone resistance may be as high-or perhaps even higher-than clarithromycin resistance in North America ( 122,141,142 ). Levofl oxacin triple therapy for 10-14 days appears to provide a comparable alternative to clarithromycin triple therapy.…”

Section: Levofl Oxacin-based Therapiesmentioning

confidence: 99%

“…Although current large scale data on H. pylori antibiotic resistance in North America are unavailable, recent data from Houston suggest that clarithromycin resistance rates may now fall within that range ( 122 ). In the absence of local or even regional H. pylori antibiotic resistance data, it is very important to ask patients about previous exposure to antibiotics for any reason, particularly macrolides and fl uoroquinolones, as this provides a proxy for underlying H. pylori antibiotic resistance ( 123,124 ).…”

Section: Clarithromycin Triple Therapymentioning

confidence: 99%

See 1 more Smart Citation

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection

Chey

Leontiadis

Howden

et al. 2017

American Journal of Gastroenterology

1,326

1,505

View full text Add to dashboard Cite

Helicobacter pylori ( H. pylori ) infection is a common worldwide infection that is an important cause of peptic ulcer disease and gastric cancer. H. pylori may also have a role in uninvestigated and functional dyspepsia, ulcer risk in patients taking low-dose aspirin or starting therapy with a non-steroidal anti-infl ammatory medication, unexplained iron defi ciency anemia, and idiopathic thrombocytopenic purpura. While choosing a treatment regimen for H. pylori , patients should be asked about previous antibiotic exposure and this information should be incorporated into the decision-making process. For fi rst-line treatment, clarithromycin triple therapy should be confi ned to patients with no previous history of macrolide exposure who reside in areas where clarithromycin resistance amongst H. pylori isolates is known to be low. Most patients will be better served by fi rst-line treatment with bismuth quadruple therapy or concomitant therapy consisting of a PPI, clarithromycin, amoxicillin, and metronidazole. When fi rst-line therapy fails, a salvage regimen should avoid antibiotics that were previously used. If a patient received a fi rst-line treatment containing clarithromycin, bismuth quadruple therapy or levofl oxacin salvage regimens are the preferred treatment options. If a patient received fi rst-line bismuth quadruple therapy, clarithromycin or levofl oxacin-containing salvage regimens are the preferred treatment options. Details regarding the drugs, doses and durations of the recommended and suggested fi rst-line and salvage regimens can be found in the guideline. Asia and Central and South America ( 8,22 ). Th ere is, however, preliminary evidence that it may be falling in some previously high prevalence areas ( 22 ). People immigrating to North America from Asia and other parts of the world have a much higher prevalence of the infection than people born in North America ( 23 ). In one study, the seroprevalence among immigrants from East Asia was 70.1% ( 24 ). Hispanic immigrants to North America have higher rates of the infection than fi rst-or second-generation Hispanics who were born here ( 25 ). QUESTION 2: WHAT ARE THE INDICATIONS TO TEST FOR, AND TO TREAT, H. PYLORI INFECTION? RecommendationsSince all patients with a positive test of active infection with H. pylori should be off ered treatment, the critical issue is which patients should be tested for the infection (strong recommendation, quality of evidence: not applicable), All patients with active peptic ulcer disease (PUD), a past history of PUD (unless previous cure of H. pylori infection has been documented), low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma, or a history of endoscopic resection of early gastric cancer (EGC) should be tested for H. pylori infection. Th ose who test positive should be off ered treatment for the infection (strong recommendation, quality of evidence: high for active or history of PUD, low for MALT lymphoma, low for history of endoscopic resection of EGC).In patients with uninvestigated d...

show abstract

Section: Levofl Oxacin-based Therapiesmentioning

confidence: 99%

Section: Clarithromycin Triple Therapymentioning

confidence: 99%

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection

Chey

Leontiadis

Howden

et al. 2017

American Journal of Gastroenterology

1,326

1,505

View full text Add to dashboard Cite

show abstract

“…According to Graham et al [119] , in the presence of fluoroquinolone resistance treatment success with quinolone-containing therapy decreases and these results can be predicted using a formula. A report published in United States in 2015 determined that the prevalence of levofloxacin resistance was 31.3% (95%CI: 23.1%-39.4%) [120] and another study showed a high rate of quinolone resistance (50%) in Congo [121] . We calculated the effect of quinolone resistance on treatment success using the proposed formula, which indicated success rates of 87.6% and 73.5%, respectively [119,122] .…”

Section: Quinolones To Existing Treatmentmentioning

confidence: 99%

Antibiotic treatment forHelicobacter pylori: Is the end coming?

Kim

Choi

Chung

2015

WJGPT

View full text Add to dashboard Cite

Infection with the Gram-negative pathogen Helicobacter pylori (H. pylori ) has been associated with gastroduodenal disease and the importance of H. pylori eradication is underscored by its designation as a group I carcinogen. The standard triple therapy consists of a proton pump inhibitor, amoxicillin and clarithromycin, although many other regimens are used, including quadruple, sequential and concomitant therapy regimens supplemented with metronidazole, clarithromycin and levofloxacin. Despite these efforts, current therapeutic regimens lack efficacy in eradication due to antibiotic resistance, drug compliance and antibiotic degradation by the acidic stomach environment. Core tip: This article reviews the recent literature describing antibiotic resistance and trends in Helicobacter pylori (H. pylori ) treatment. As there is no effective conventional therapy, new treatments are being developed and bismuth quadruple, sequential, concomitant therapies are recommended as a first-line regimen in regions with high levels of clarithromycin resistance. Quinolones have also been used for H. pylori treatment, although the cure rate has gradually reduced with this approach. New therapeutic directions include probiotic supplementation, tailored therapy, novel agents, and nanotechnology.

show abstract

“…In Brazil, resistance to amoxicillin has been detected in 29% of strains recovered from post-treatment [39]. However, many studies from other countries have shown that all strains examined are susceptible to amoxicillin [42,43]. The clinical significance of amoxicillin susceptibility testing has not been yet documented.…”

mentioning

confidence: 99%

Molecular characterization and antibiotic susceptibility profiles of Helicobacter pylori isolated from patients with Gastrodeudenal diseases in Jordan

Abu-Qatouseh

Abu-Sini

Mayyas

et al. 2016

int. arab. j antimicrob. agents

View full text Add to dashboard Cite

Introduction: Helicobacter pylori is a major cause of more than 80% of chronic active gastritis and other gastrodeudonal diseases worldwide. Successful treatment of H. pylori routinely requires the use of multiple agents with different mechanisms including compounds inhibiting acid secretion in conjunction with antibiotics. However, recent data showed the emergence of resistant clinical strains particularly against metronidazole and clarithromycin. The aim of this study is to determine the prevalence of and the susceptibility of H. pylori isolates recovered from patients with gastrodeudonal diseases to several antimicrobial agents.

show abstract

Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans

Abstract: H pylori resistance to clarithromycin increased between 2009 and 2013; resistance to metronidazole remains high in infected men in the United States. The high frequency of resistance to levofloxacin is a new and concerning finding.

Cited by 136 publications

References 41 publications

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection

Antibiotic treatment forHelicobacter pylori: Is the end coming?

Molecular characterization and antibiotic susceptibility profiles of Helicobacter pylori isolated from patients with Gastrodeudenal diseases in Jordan

Contact Info

Product

Resources

About